0.2785
Cyclacel Pharmaceuticals Inc Aktie (CYCC) Neueste Nachrichten
Cyclacel Pharmaceuticals expands share authorization By Investing.com - Investing.com India
Major Shareholders Set to Sell Stocks; Company (TICKER) to Reap No Proceeds | CYCC Stock News - GuruFocus
Cyclacel Pharmaceuticals Inc Inc. (CYCC) Price Performance: A Technical Analysis Perspective - investchronicle.com
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) Could Actually Go To 1 In 12 Months - Marketing Sentinel
Cyclacel Pharmaceuticals (CYCC) Announces Quarterly Dividend - GuruFocus
Was Cyclacel Pharmaceuticals Inc (CYCC)’s session last reading good? - uspostnews.com
StockNews.com Initiates Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Trading (CYCCP) With Integrated Risk Controls - news.stocktradersdaily.com
Cyclacel Pharmaceuticals announces preferred stock dividend By Investing.com - Investing.com Canada
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated at StockNews.com - Defense World
When (CYCCP) Moves Investors should Listen - news.stocktradersdaily.com
Cyclacel Pharmaceuticals Inc (CYCC) Q2 2024 Earnings Call Transc - GuruFocus
Fitters Diversified To Dispose Subsidiary To Nasdaq Listed Pharma Firm - businesstoday.com.my
Fitters plans to sell full stake in unit to US biotech firm - The Malaysian Reserve
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update - The Manila Times
Cyclacel Pharmaceuticals Shifts Focus to Cancer Drug Development - TipRanks
Cyclacel Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Cyclacel Pharmaceuticals Appoints New Directors Amid Strategic Shift - TipRanks
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results And Provides Business Update - MarketScreener
Cyclacel Pharmaceuticals Delays 10-K Filing - TipRanks
CYCC stock touches 52-week low at $0.29 amid sharp annual decline By Investing.com - Investing.com South Africa
CYCC stock touches 52-week low at $0.29 amid sharp annual decline - Investing.com
Financial Contrast: Cellectar Biosciences (NASDAQ:CLRB) versus Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Cyclacel Pharmaceuticals to offer convertible preferred stock in private placement - MSN
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering Of Convertible Preferred Stock - Marketscreener.com
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock - The Manila Times
Cyclacel's Latest $1M Financing Deal Reveals Extended Survival Strategy Through Q3 2025 - Stock Titan
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com - Defense World
Cyclacel Pharmaceuticals’ Change of Control Transaction and Appointment of New Executive Leadership - Global Legal Chronicle
(CYCCP) Trading Advice - news.stocktradersdaily.com
Cyclacel Pharmaceuticals (CYCC) Projected to Post Earnings on Tuesday - The AM Reporter
CYCLACEL PHARMACEUTICALS Earnings Preview: Recent $CYCC Insider Trading, Hedge Fund Activity, and More - Nasdaq
StockNews.com Begins Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Cyclacel Pharmaceuticals acquires cancer drug assets By Investing.com - Investing.com Australia
Cyclacel Pharmaceuticals acquires cancer drug assets - Investing.com
Cyclacel stock plunges to 52-week low at $0.3 amid market challenges - Investing.com Australia
Cyclacel stock plunges to 52-week low at $0.3 amid market challenges By Investing.com - Investing.com South Africa
Cyclacel Pharmaceuticals (CYCC) to Release Earnings on Tuesday - Defense World
Cyclacel stock plunges to 52-week low of $0.31 amid market challenges - MSN
Cyclacel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Cyclacel Pharmaceuticals interim CEO David Lazar sells $5.5 million in stock - Investing.com India
Cyclacel Pharmaceuticals Announces New Leadership and Restructuring - TipRanks
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):